Recent Updates
Recently added Catalysts
BFRI

Biofrontera Inc. to Participate in The Benchmark Healthcare House Call Virtual 1x1 Conference

Key Takeaway: WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1
Price reaction · baseline $58.8 (2022-05-27 close) · hit after-hours · clean, no other BFRI news in the window
day 0 close · peak
-2.4%

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+65%
120-day peak, hindsight
Typical move
14.8%
average across 3 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
BF-200 ALA 1%
Phase 2 · Actinic Keratosis

Full Press Release Details

WOBURN, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, announced today that the Company will be participating in The Benchmark Healthcare House Call Virtual 1x1 Conference being held on June 2, 2022.
Erica Monaco, Chief Executive Officer and Hermann Lübbert, Executive Chairman of Biofrontera Inc. will be meeting with registered investors in virtual one-on-one meetings and small-group sessions.
About Biofrontera Inc.
Biofrontera Inc. is a U.S.-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on PDT and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. For more information, visit https://www.biofrontera-us.com.
Last updated: May 31, 2022